| 0 (0%) | 01-14 09:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.6 | 1-year : | 25.23 |
| Resists | First : | 18.5 | Second : | 21.6 |
| Pivot price | 16.65 |
|||
| Supports | First : | 16.07 | Second : | 14.57 |
| MAs | MA(5) : | 16.95 |
MA(20) : | 16.55 |
| MA(100) : | 15.44 |
MA(250) : | 11.71 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.5 |
D(3) : | 50.8 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 20.76 | Low : | 6.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADPT ] has closed below upper band by 0.8%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.51 - 18.6 | 18.6 - 18.69 |
| Low: | 17.18 - 17.29 | 17.29 - 17.4 |
| Close: | 17.86 - 18.04 | 18.04 - 18.22 |
Tue, 13 Jan 2026
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Tue, 13 Jan 2026
What's Going On With Adaptive Biotechnologies Shares Tuesday? - Benzinga
Tue, 13 Jan 2026
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Revenue Growth Surges Over 100%, Analysts Eye 9.53% Upside - DirectorsTalk Interviews
Mon, 12 Jan 2026
ADPT: MRD and immune medicine platforms drive growth, profitability, and new pharma partnerships in 2026 - TradingView — Track All Markets
Mon, 12 Jan 2026
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - Still a Buy? - MarketBeat
Mon, 12 Jan 2026
Adaptive Biotechnologies (ADPT) Surpasses Q4 Revenue Estimates, Shares Climb - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 153 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 96.8 (%) |
| Shares Short | 9,740 (K) |
| Shares Short P.Month | 10,370 (K) |
| EPS | -0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.34 |
| Profit Margin | -31.5 % |
| Operating Margin | 10.9 % |
| Return on Assets (ttm) | -9.4 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | 102.4 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 1.65 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -34.75 |
| PEG Ratio | 0 |
| Price to Book value | 13.48 |
| Price to Sales | 10.91 |
| Price to Cash Flow | -45.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|